BRAF V600E突变在接受免疫检查点抑制剂治疗的MSI-high转移性结直肠癌患者中的预后影响
这项回顾性国际研究纳入2014年至2023年间接受免疫检查点抑制剂(ICI)治疗、且有BRAF突变状态的dMMR/MSI转移性结直肠癌患者909例,其中345例(38%)为BRAF V600E突变。总体人群中BRAF突变与ICI起始后的PFS和OS无显著关联,但一线治疗患者中BRAF突变者继发性耐药率更高、6个月疾病控制后的PFS和OS更短;抗PD1联合抗CTLA4治疗时未再观察到该不良预后影响。
要点
- 总体人群BRAF突变与ICI治疗后的PFS和OS无显著关联(adjHR分别为0.97和0.98)。
- 一线治疗中BRAF突变者继发性耐药率20% vs 11%(p=0.02),6个月疾病控制后PFS和OS更短。
- 抗PD1联合抗CTLA4治疗时未再观察到BRAF突变的不良预后影响。
核心结论
- 在dMMR/MSI转移性结直肠癌患者中,总体人群(全部治疗线数)接受ICI治疗时BRAF V600E突变与较短的PFS/OS无关。
- 但在一线治疗患者中,结果提示BRAF突变与更高的继发性耐药率相关,作者认为一线联合PD1和CTLA4抑制剂在这些患者中可能特别有意义。
研究设计与样本
- 回顾性国际研究,纳入2014年至2023年间接受ICI治疗(全部线数)且有BRAF突变状态的dMMR/MSI转移性结直肠癌患者909例。
- 345例(38%)为BRAF V600E dMMR/MSI转移性结直肠癌。
主要发现
- 多变量分析中,BRAF突变与BRAF野生型患者相比,ICI起始后PFS中位25.0个月 vs 41.5个月(adjHR=0.97,p=0.8),OS中位55.1个月 vs 未达到(adjHR=0.98,p=0.9),均无显著关联。
- 一线ICI治疗患者中,继发性耐药(定义为治疗前6个月后进展)率BRAF突变者20% vs 11%(p=0.02),BRAF突变者更高。
- 一线治疗中获得6个月疾病控制的患者,自该时点起的PFS和OS在BRAF突变者中显著更短(PFS adjHR 2.09,p=0.03;OS adjHR 2.80,p=0.019)。
- 接受抗PD1联合抗CTLA4治疗的患者中,未再观察到BRAF突变的不良预后价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prognostic impact of the BRAF V600E mutation in patients with deficient mismatch repair (dMMR)/microsatellite instability (MSI) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) is poorly understood. MATERIAL AND METHODS: This retrospective international study included patients with dMMR/MSI mCRC treated with ICI all lines between 2014 and 2023, and available BRAF mutation status. RESULTS: Of 909 patients included, 345 (38 %) had BRAF V600E dMMR/MSI mCRC. In multivariable analysis, BRAFm was not associated with a shorter progression-free survival (PFS) and overall survival (OS) from ICI start compared to BRAFwt patients (median PFS: 25.0 vs 41.5 months, adjusted hazard ratio (adjHR)= 0.97, p = 0.8 and OS: 55.1 months vs not reached adjHR= 0.98, p = 0.9). However, in patients treated with ICI in first line, the rate of secondary resistance, defined as the progression after the first 6 months of treatment, was higher in BRAFm patients (20 % vs 11 %, p = 0.02). In patients with disease control for 6 months in 1st line, the PFS and OS from this point onwards were significantly shorter in BRAFm patients (adjHR for PFS 2.09, p = 0.03 and adjHR for OS 2.80, p = 0.019). The poor prognostic value of the BRAF mutation was no longer observed in patients treated with anti-PD1 and anti-CTLA4 combination. CONCLUSIONS: In patients with dMMR/MSI mCRC, the BRAF V600E mutation is not associated with a shorter PFS/OS on ICI treatment in the overall population across all lines. However, specifically in patients treated in the first-line setting, our results suggest that the BRAF mutation is associated with a higher rate of secondary resistance, suggesting that a combination of PD1 and CTLA4 inhibitors upfront may be of particular interest in these patients.
引用
- Gallois C, Ambrosini M, Lonardi S, et al. Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2025. PMID: 40690890. doi:10.1016/j.ejca.2025.115645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。